Clasp Therapeutics took off with $150 million in Series A financing to develop a portfolio of next-generation immunotherapies that are both personalized and off-the-shelf to target hard-to-treat tumors. Based in Cambridge, Massachusetts and Rockville, Maryland, the startup garnered attention from…
Korro Bio raised $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a…
Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic…
LyGenesis, Inc., a biotechnology company developing innovative technology for organ regeneration, announced today that they have raised $3 million in Series A financing from Juvenescence, Ltd. LyGenesis’ technology uses lymph nodes as bioreactors to regrow functioning organs within a patient’s…
